Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Accumulated Expenses (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Accumulated Expenses data on record, last reported at $19.0 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 31.08% year-over-year to $19.0 million; the TTM value through Dec 2025 reached $19.0 million, up 31.08%, while the annual FY2025 figure was $19.0 million, 31.08% up from the prior year.
  • Accumulated Expenses reached $19.0 million in Q4 2025 per SNDX's latest filing, up from $15.6 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $35.7 million in Q3 2024 and bottomed at $1.6 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $12.8 million, with a median of $14.5 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: tumbled 82.11% in 2021, then surged 684.98% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $4.3 million in 2021, then surged by 231.07% to $14.4 million in 2022, then grew by 13.71% to $16.3 million in 2023, then fell by 11.43% to $14.5 million in 2024, then soared by 31.08% to $19.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $19.0 million in Q4 2025, $15.6 million in Q3 2025, and $14.5 million in Q2 2025.